Texas Urology Specialists' Dr. Jeffrey Toubin Achieves Special Designation for Breakthrough Prostate Enlargement Treatment

Toubin earns Center of Excellence designation for extensive experience with UroLift®, minimally invasive treatment for common prostate condition

Dallas, TX (November 28, 2017) – Texas Urology Specialists today announced that Jeffrey Toubin, M.D., FACS, has been designated as a UroLift® Center of Excellence. The designation recognizes Dr. Toubin’s exemplary care and his extensive training and experience with the UroLift System, technology that includes permanent implants for men suffering from benign prostatic hyperplasia or BPH. Toubin is a board-certified urologist practicing at Texas Urology Specialists–Dallas, adjacent to Methodist Dallas Medical Center.

“The UroLift System is a breakthrough minimally invasive treatment that typically takes less than an hour and can offer multiple benefits for men with enlarged prostate – no cutting, heating, or removal of tissue, minimal downtime, no compromise of sexual function, and no need for continued medications,” said Dr. Toubin. “I am proud to offer our patients this durable and effective treatment.”

Nearly 40 million men in the United States are affected by BPH. Not to be confused with prostate cancer, BPH occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems, and can cause loss of productivity, depression, and decreased quality of life.

Five-year data from a randomized study shows the UroLift System offers rapid improvement, and durable relief for patients with BPH. After five years, patients treated with the UroLift System continue to experience symptom relief with minimal side effects, with few patients requiring an additional procedure for relief.1 A second randomized clinical trial called BPH6 demonstrated that the minimally invasive UroLift System compares very well to the reference standard surgery, transurethral resection of the prostate (TURP), with regard to efficacy, and is superior to TURP at preserving sexual function and offering a more rapid recovery.2

1 Roehrborn et al. EAU Abstract_ Eur Urol Suppl 2017; 16(3):e192.
2 Sonksen et al J Urology 2016

About the UroLift System

NeoTract’s FDA-cleared UroLift System is a novel, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function. Patients also experienced a significant improvement in quality of life. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at www.UroLift.com.